Joseph Sang-II Kwon

Sep 30, 2024 | nature.com | Richard McManus |Clare Taylor |Nicholas Jones |Jane Wolstenholme |Sungwook Kim |Joseph Sang-II Kwon | +2 more

AbstractChronic kidney disease (CKD) is associated with a substantial risk of progression to end-stage renal disease and vascular events. The nonsteroidal mineralocorticoid receptor antagonist (MRA), finerenone, offers cardiorenal protection for people with CKD and diabetes, but there is uncertainty if the steroidal MRA, spironolactone, provides the same protection.

Sep 16, 2024 | dovepress.com | Adam Smith |Darren Greenwood |Paul Williams |Joseph Sang-II Kwon

Back to Journals » Patient Related Outcome Measures » Volume 16 Authors Smith AB , Greenwood DC , Williams P, Kwon J , Petrou S, Horton M , Osborne T, Milne R, Sivan M Received 16 September 2024 Accepted for publication 3 January 2025 Published 25 January 2025 Volume 2025:16 Pages 55—66 DOI https://doi.org/10.2147/PROM.S490870 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Robert Howland Adam B Smith,1 Darren C...

Aug 11, 2024 | medrxiv.org | Adam Smith |Darren Greenwood |Paul Williams |Joseph Sang-II Kwon

The authors have declared no competing interest. This work is independent research funded by the National Institute for Health and Care Research (NIHR) grant Ref COV-LT2-0016. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Apr 12, 2024 | mdpi.com | Nawar Diar Bakerly |Julie L. Darbyshire |Joseph Sang-II Kwon

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Nov 10, 2023 | mdpi.com | Joseph Sang-II Kwon |Corneliu Bolbocean |Olu Onyimadu |Nia Roberts

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.